VAXIMM

VAXIMM, a vaccine company based in Switzerland developing immunotherapies for cancer patients, offers VXM01 targeting tumor vasculature.

Vaximmis a privately held, Swiss-based vaccine company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011. Vaximmwas formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA to develop VXM01.